Study on application of LiveSpo® Navax in treatment of Acute Respiratory Tract Infections due to RSV (Respiratory syncytial virus) and influenza virus

Respiratory syncytial virus ̣(RSV) and influenza virus are the leading cause of Upper Repiratory Tract Infections. Thiss clinical study was conducted for initial assessment of supportive treatment effects of nasal-spraying liquid suspension Bacillus spores (Bacillus subtilis ANA4 and Bacillus clausii ANA39) – LiveSpo Navax in RSV and influenza virus infected children in Vietnam National Children’s Hospital. 

The results of study show that: The group of patients using LiveSpo Navax (Navax group) had 1-2 days faster recovery time in relieving typical symptoms in comparison with control group, relying on each symptoms (runny nose, difficulty breathing, dry raltes, moist rales, chest despression and fever). After 48-h and 72-h of influenza and RSV treatment respectively, the concentration of influenza virus, RSV and two superinfected bacteria (Haemophilus influenza và Streptococcus pneumoniae) in nasopharyngeal samples of patients reduced by about 3 x 102 folds, 1 x 103 folds and more than 1x 104 folds respectively, while in the control group, there was found only 15-folds reduction in both RSV and influenza virus concentraion but concentration of H. Influenza was increased and decreased depending on the case. The decrease of RSV, influenxa virus and superinfected bacteria concentration is relevant to present of spore probiotics B. subtilis and B. clausii in nasopharyngeal sample of patients in Navax group while these spores were not detected in control group. We did not record any case with abnormal changes of breathing, pulse, nasal irritation or digestion. 

This is the world’s first blind, randomize and controlled clinical trial in children to demonstrated the safety and beneficial effects of nasal-spraying product containing Bacillus spore probiotics. Spraying LiveSpo Navax into nasal cavity, 3 times a day, help shortening the recovery time for typical symptoms of upper respiratory tract infection cause by RSV and influenza virus by 1-2 days, depending on each symptom. It also help reducing the concentration of RSV, influenza virus and superinfected bacteria in nasopharyngeal samples of patients at about 20-70 folds more effectiveness than physiological saline